Steven A. Rosenberg, MD, PhD [clinicaltrials_resource:200e3f0cfe4e2debc8a8c94841b9ca82]
Gene Therapy and Biological Therapy in Treating Patients With Ovarian Epithelial Cancer [clinicaltrials:NCT00019136]Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Recurrent Metastatic Melanoma [clinicaltrials:NCT00019175]Vaccine Therapy in Treating Patients With Recurrent or Refractory Metastatic Melanoma [clinicaltrials:NCT00019383]Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma [clinicaltrials:NCT00019487]Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma [clinicaltrials:NCT00019669]Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma [clinicaltrials:NCT00019721]Vaccine Therapy in Treating Patients With Metastatic Melanoma [clinicaltrials:NCT00019994]Vaccine Therapy in Treating Patients With Melanoma [clinicaltrials:NCT00020358]Vaccine Therapy in Treating Patients With Refractory Metastatic Melanoma [clinicaltrials:NCT00020397]Vaccine Therapy in Treating Patients With Metastatic Cancer [clinicaltrials:NCT00021164]Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma That Has Not Responded to Previous Treatment [clinicaltrials:NCT00022438]Vaccine Therapy and Monoclonal Antibody Therapy in Treating Patients With Stage IV Melanoma [clinicaltrials:NCT00032045]Monoclonal Antibody Therapy and Interleukin-2 in Treating Patients With Metastatic Melanoma [clinicaltrials:NCT00058279]Lymphocyte-Depleting Nonmyeloablative Preparative Chemotherapy Followed By Autologous Lymphocyte Infusion, Peptide Vaccine Plus Montanide ISA-51, and Interleukin-2 in Treating Patients With Metastatic Melanoma [clinicaltrials:NCT00079144]Denileukin Diftitox in Treating Patients With Metastatic Melanoma or Metastatic Kidney Cancer [clinicaltrials:NCT00082914]LMB-2 Immunotoxin and Vaccine Therapy in Treating Patients With Metastatic Melanoma That Cannot Be Removed By Surgery [clinicaltrials:NCT00295958]Tumor Necrosis Factor in Patients Undergoing Surgery for Primary Cancer or Metastatic Cancer [clinicaltrials:NCT00436410]clinicaltrials:NCT00492440
overall official [clinicaltrials_vocabulary:overall-official]
Steven A. Rosenberg, MD, PhD [clinicaltrials_resource:200e3f0cfe4e2debc8a8c94841b9ca82]
Bio2RDF identifier
200e3f0cfe4e2debc8a8c94841b9ca82
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:200e3f0cfe4e2debc8a8c94841b9ca82
affiliation [clinicaltrials_vocabulary:affiliation]
last name [clinicaltrials_vocabulary:last-name]
Steven A. Rosenberg, MD, PhD
role [clinicaltrials_vocabulary:role]
Study Chair
identifier
clinicaltrials_resource:200e3f0cfe4e2debc8a8c94841b9ca82
title
Steven A. Rosenberg, MD, PhD
@en
type
label
Steven A. Rosenberg, MD, PhD [clinicaltrials_resource:200e3f0cfe4e2debc8a8c94841b9ca82]
@en